Johnson & Johnson (JNJ)vsStevanato Group SpA (STVN)
JNJ
Johnson & Johnson
$282.84
-1.12%
HEALTHCARE · Cap: $682.52B
STVN
Stevanato Group SpA
$15.53
-1.71%
HEALTHCARE · Cap: $3.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 7859% more annual revenue ($99.33B vs $1.25B). JNJ leads profitability with a 16.2% profit margin vs 11.3%. STVN appears more attractively valued with a PEG of 1.70. STVN earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy54
out of 100
Grade: C-
STVN
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for JNJ.
Margin of Safety
+67.9%
Fair Value
$48.58
Current Price
$15.53
$33.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 26.6%
Generating 6.4B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Trading at 8.4x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Expensive relative to growth rate
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.
Bull Case : STVN
The strongest argument for STVN centers on Debt/Equity, Price/Book.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.
Bear Case : STVN
The primary concerns for STVN are PEG Ratio, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while STVN is a value play — different risk/reward profiles.
STVN carries more volatility with a beta of 0.80 — expect wider price swings.
STVN is growing revenue faster at 7.6% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
STVN scores higher overall (59/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Stevanato Group SpA
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in innovative glass and polymer packaging solutions designed for injectable medications used by the pharmaceutical and biotechnology industries. With a steadfast focus on quality, sustainability, and the adoption of cutting-edge technologies, Stevanato is well-positioned to benefit from the burgeoning demand within the biopharmaceutical sector. The company’s dedication to enhancing the efficiency and reliability of drug administration makes it an attractive proposition for institutional investors looking for opportunities in healthcare innovation and sustainable growth.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?